Beneficial properties of Passiflora caerulea on experimental colitis.
BACKGROUND
Passiflora caerulea L. (Passifloraceae) is a medicinal plant commonly used in traditional medicine in South America for different pathologies associated with the gastrointestinal tract.


OBJECTIVE
In the present study, the activity of the ethanolic extract of P. caerulea on an experimental colitis model related to inflammatory bowel disease has been investigated.


METHODS
Colitis was induced by intracolonic instillation of a 2mL of 4% (v/v) acetic acid solution. Macroscopic scoring, myeloperoxidase activity and thiobarbituric acid reactive substances levels were evaluated on isolated colon mucosae. The histopathological studies of colon mucosae were performed by hematoxylin and eosin and Alcian blue staining. Diarrhoea was induced by the administration of castor oil (0.3mL/mouse). The first watery defecation time, the total amount of solid, semi-solid and watery stools and the amount of watery stools were determined. The effect of the extract on a cumulative concentration-response curve of acetylcholine and CaCl2on isolated rat jejunum was also evaluated. The phytochemical analysis was performed.


RESULTS
The extract (250mg/kg, p.o.) induced a significant reduction in the weight/length ratio, the macroscopic lesion score, TBARS levels and the microscopic tissue damage when compared with the acetic acid-treated group of animals. P. caerulea (125mg/kg, p.o.) decreased significantly the amount of watery stools in the castor oil-induced-diarrhoea model. Moreover, the P. caerulea extract antagonized the jejunum contractions induced by Ach (Emaxfor 0.3mg/mL: 76.25%; Emaxfor 1mg/mL: 63.47%; Emaxfor 3mg/mL: 42.01%) and CaCl2(Emaxfor 0.3mg/mL: 75.69%; Emaxfor1 mg/mL: 56.1%; Emaxfor 3mg/mL: 53.4%). Isoorientin, vitexin, isovitexin, and vicenin-2 were identified in the extract.


CONCLUSIONS
P. caerulea showed anti-inflammatory, anti-diarrhoeal and spasmolityc activities on preclinical models.
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacología, Junín 956, C1113AAD Buenos Aires, Argentina.
M L
ML
Anzoise
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacognosia,IQUIMEFA, CONICET, Junín 956, C1113AAD Buenos Aires, Argentina.
C
C
Marrassini
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacobotánica, Junín 956, C1113AAD Buenos Aires, Argentina.
H
H
Bach
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacología, Junín 956, C1113AAD Buenos Aires, Argentina. Electronic address: sgorza@ffyb.uba.ar.
S
S
Gorzalczany
D000818:Animals; D003092:Colitis / Q000188:drug therapy*; D004195:Disease Models, Animal; D005260:Female; D051379:Mice; D029598:Passiflora / Q000737:chemistry*; D010936:Plant Extracts / Q000627:therapeutic use*
D010936:Plant Extracts
Anti-inflammatory; Antioxidant activity; Antispasmodic; Histological study; Passiflora caerulea; Ulcerative colitis model